Our co-founders Kunwoo Lee, Ph.D., Hyo Min Park, Ph.D., and Niren Murthy, Ph.D., worked closely with Nobel Laureate Jennifer Doudna, Ph.D., (Chemistry, 2020) at UC Berkeley and recognized that identifying the right delivery strategy was the critical step in realizing the potential of CRISPR/Cas9 and other genetic medicines. GenEdit’s mission is to develop innovative therapies through targeted delivery of genetic medicines. With our team’s collective expertise, we are currently advancing novel therapies and realizing our vision to revolutionize genetic medicine through therapies that rewrite patient health.

NanoGalaxy® Platform : At GenEdit, we are overcoming this limitation with our proprietary technology, NanoGalaxy®. Our NanoGalaxy platform contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.

Private

Biotech